September 30, 2025 · Form 4 insider transaction
Sweiti Hussein bought 600,000 shares of enGene Therapeutics Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
Non-qualified stock option grant awarded as an inducement award outside of the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This option vests at 25% on September 29, 2026, which is the first anniversary of the employment commencement date, with the remaining portion to vest monthly over the remaining three years, subject to the reporting person's continued service.